Kyntra Bio (LTS:0IL8) Valuation Rank


LTS:0IL8 Kyntra Bio Inc LTS:0IL8
50 GF Score
Price $7.45
GF Value $5.70
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Kyntra Bio Valuation Rank Related Terms

LTS:0IL8
50GF Score
Kyntra Bio Inc LTS:0IL8
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $7.45 is trading 30.8% above its estimated GF Value™ of $5.70. GuruFocus considers Kyntra Bio to be Significantly Overvalued.

Key valuation signals for LTS:0IL8:

  • Valuation Rank:
  • GF Value™: $5.70 vs. price of $7.45 (30.8% above fair value)
  • GF Score™: 50/100 with 8 warning signs

No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
50GF Score

Get the complete analysis for LTS:0IL8

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price
$5.70
GF Value